Overview

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

Status:
Completed

Trial end date:
2017-04-04

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of daily subcutaneous administration of 5 μg/kg tbo-filgrastim in infants, children and adolescents with solid tumors without bone marrow involvement.

Phase:

Phase 2

Details

Lead Sponsor:

Teva Pharmaceutical Industries
Teva Pharmaceutical Industries, Ltd.

Treatments:

Lenograstim